EUROPEAN COMMISSION
JOINT RESEARCH CENTRE

Directorate F – Health and Food
Disease Prevention

Annual Declaration of Interests[1] (DoI) form
(v2, 01 July 2026)

European Commission initiative on Lung Cancer (EC-LuC)

Please answer each of the questions below.
If the answer to any of the questions is "Yes"[2], please complete the corresponding fields, describing the circumstances, as appropriate.

If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the EC-LuC activities.
If you do not disclose relevant activities of interest for the EC-LuC, your role may be revised.

[1] According to EC's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 10, each member of an expert group has to complete a DoI form
https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en

[2] Answering "Yes" to the questions on this form does not automatically limit your participation in the EC-LuC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (*i.e.* any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

Name and Surname:	PILAR GARRIDO LÓPEZ

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
1. Do you have current investments[3] in a legal entity[4] with an interest related to lung cancer which either: **• has a value of more than 10.000 EUR, or** **• entitles you to a voting right of 5% or more?**	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of entity; • Place; • Type of entity: public, private.	[Please describe your role.]

[3] **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (*e.g.*, proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).

[4] **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
2. Within the past 5 years, were you employed (remunerated or non-remunerated post) or have you had any other professional relationship with a legal entity or any other body, with an interest related to lung cancer? **A. Employment**	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of the entity; • Place; • Type of entity: public, private; • Received amounts for remunerated activities.	[Please describe your role.]

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
B. Consultancy, including advisory activities	Yes ☒ No ☐	01/2021–12/2025	If 'yes', please specify: • Name of the entity; • Place; • Type of the entity: public, private; • Received amounts for remunerated activities.	I have participated in advisory councils/committees for AbbVie, Amgen, AstraZeneca, Bayer, BeOne, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Gilead, IO Biotech, Johnson & Johnson, Lilly, Merck Sharpe & Dohme, Novartis, PharmaMar, Pierre Fabre, Pfizer, Regeneron, Roche. Speakers Bureau: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Lilly, Merck Sharpe & Dohme, PharmaMar, Regeneron,
C. Non-remunerated post	Yes ☒ No ☐	01/2021–12/2025	If 'ye's, please specify: • Name of the entity; • Place; • Type of the entity: public, private;	Chair of the National Technical Council of the Spanish Association Against Cancer (AECC) and as Trustee of the AECC Scientific Foundation.
D. Legal representation[5]	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of the entity; • Place; • Type of the entity: public, private;	[Please describe your role.]

[5] **Legal representation** refers to the representation of natural or legal persons through other persons in accordance with national law. For example, the president of a company is the legal representative of that company.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
3. Regarding research related to lung cancer within the past 5 years: **A. Have you been an investigator in research studies on lung cancer?**	Yes ☒ No ☐	01/2021–01/2025	PI: PREMIUM (Predictive ExtreMe response to Immunotherapy in lUng cancer through Microbiota fingerprint) project (2023-2026): 93.170 Euros Co-PI MORELIA study (Microbiota transplant in advanced lung cancer treated with immunotherapy), 2021-2024; 322.025 Euros Local PI: INGENIO ("INtegrative GENomic, digital Imaging and clinical information towards Precision Oncology project. 2022-2025; 223.000 Euros	Chair of the Translational Lung Cancer Research Group at the Ramón y Cajal Health Research Institute (IRYCIS) and the affiliated Thoracic Tumours Clinical Research Group within CIBERONC (Spanish Biomedical Research Networking Centre in Oncology). As principal investigator, I have been granted with several nationally funded competitive research projects), including the PREMIUM Project (PI22/01588), investigating microbiome signatures associated with exceptional responses to immunotherapy; the INGENIO Project (PMP21/00107), focused on integrative precision oncology; and the MORELIA academic clinical trial (IC20/00058), evaluating faecal microbiota transplantation in patients with advanced lung cancer treated with immunotherapy.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
B. If yes, for the aforementioned research studies, did you receive support[6]?	Yes ☒ No ☐	MM/YYYY – MM/YYYY	If 'yes', please specify: • Type of received support: grants, funds; • Entity which offered the support: name, place, type (public, private); • Received amounts (for public grants please also specify the annual budget of your home institution).	Research funding obtained through competitive calls from the Spanish Instituto de Salud Carlos III (ISCIII), Spain's main public health research and biomedical research funding agency. PI: PREMIUM (Predictive ExtreMe response to Immunotherapy in lUng cancer through Microbiota fingerprint) project (2023-2026): 93.170 Euros Co-PI MORELIA (Microbiota transplant in advanced lung cancer treated with immunotherapy) study, 2021-2024; 322.025 Euros Local PI: INGENIO ("INtegrative GENomic, digital Imaging and clinical information towards Precision Oncology project. 2022-2025; 223.000 Euros

[6] **Support** refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
4. Do you have membership in national or international organisations[7], including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies or any decision making bodies with an interest in lung cancer?	Yes ☒ No ☐	01/2021–12/2025	If 'yes', please specify: • Name, • Place; • Type: public, private, etc. (list all if more than one).	Member of the European Society of Medical Oncology (ESMO) and ESMO Fellow, member of the International Association for Study of Lung Cancer (IASLC) and part of the IASLC Academy. Co-founder of ICAPEM (Spanish research association focused on gender differences in lung cancer). Former president of the Spanish Medical Oncology Society (SEOM). Former president of the Federation of Spanish Medical Associations (FACME)
5. Do you have intellectual property rights (IPR)[8] related to lung cancer?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please specify the title of the IPR.	[Please describe the IPR.]

[7] **Organisation** refers to a governmental, international or non-profit organisation.

[8] **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
6. Within the past 5 years: **A. Have you provided any expert opinion or testimony in the field of lung cancer, for a legal entity or other body as part of a regulatory, legislative or judicial process?**	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please mention the activity.	[Please describe the activity.]
B. Have you held an office or other position, paid or unpaid, where you represented interests or defended an opinion in the field of lung cancer?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please mention the activity.	[Please describe the activity.]
7. Do any of your immediate family members[9] have direct interests related to lung cancer that could undermine your independence?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please mention the interest.	[Please describe the interest.]

[9] **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
8. Within the past 5 years, did you take part in other activities with interests related to lung cancer?	Yes ☒ No ☐	MM/YYYY – MM/YYYY	Please specify the title of the activity.	Scientific Committee member of the Lung Cancer Alliance Scientific Committee member of the Spanish lung cancer patient association (AEACAP)

Notes:

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published[10] before you send the DoI form to the Joint Research Centre (JRC), EC.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending an e-mail as soon as possible at: JRC-CANCER-POLICY-SUPPORT@ec.europa.eu.

☒ **I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.**

☒ **I agree my DoI form to be publicly available on the EC's web-hub on cancer screening and care, during the EC-LuC membership[11].**

☒ **I am informed that my personal data are stored, processed and published by the EC in accordance with Regulation (EU) 2018/1725[12].**

Name and Surname: **PILAR GARRIDO LÓPEZ** **Date:** **17 JUL 2026**

Signature: GARRIDO LOPEZ MARIA PILAR - 50304925S Firmado digitalmente por GARRIDO LOPEZ MARIA PILAR - 50304925S Fecha: 2026.07.17 18:39:50 +02'00'

Place: **Madrid**

[10] Personal data processing including the DoI
https://ec.europa.eu/dpo-register/detail/DPR-EC-00656
[11] Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.
[12] Protection of individuals with regard to the processing of personal data
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725